Sigilon Therapeutics, Inc.
SEC CIK 1821323 · SGTX · last insider filing 2023-08-15
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Oesterle Stephen N. | Director | filed 2020 - 2023 |
| Ruffolo Robert R | Director | filed 2020 - 2023 |
| Cole Douglas G. | Director | filed 2020 - 2023 |
| Cox John | Director | filed 2020 - 2023 |
| Vivaldi Coelho Rogerio | Director · President and CEO | filed 2020 - 2023 |
| Shaff Eric D. | Director | filed 2020 - 2023 |
| Patel Kavita | Director | filed 2020 - 2023 |
| Story Brooke | Director | filed 2021 - 2022 |
| Anderson Daniel Griffith | Director | filed 2020 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Kowalsky Matthew Paul | CHIEF OF STAFF AND CLO | filed 2023 - 2023 |
| Ashton-Rickardt Philip | Chief Scientific Officer | filed 2021 - 2023 |
| Pontes Josias | VP, Head of Finance | filed 2021 - 2023 |
| Yuan Qing Sarah | CTOO | filed 2022 - 2023 |
| Orfali May | CHIEF MEDICAL OFFICER | filed 2021 - 2022 |
| Reicin Glenn | Chief Financial Officer | filed 2020 - 2021 |
| Smith Devyn | Chief Operating Officer | filed 2020 - 2021 |
| Corzo Deya | Chief Medical Officer | filed 2020 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.